Risk factors
Vanda Pharmaceuticals (VNDA) risk factors
Item 1A of every Vanda Pharmaceuticals Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors64 risks9 new2 dropped20 reworded
Vanda faces generic competition for HETLIOZ after court losses and relies heavily on regulatory approvals for new pipeline candidates like NEREUS and Bysanti.
Filed Feb 12, 2026 - FY2024 10-K risk factors57 risks
Vanda Pharmaceuticals is heavily dependent on the commercial success of Fanapt, HETLIOZ, and PONVORY.
Filed Feb 14, 2025